ORPHA:221046
Poikiloderma with neutropenia
Also known as: Poikiloderma with neutropenia, Clericuzio type
Query health: suspect — Only one of 2 strategies returned hits (phrase).
Publications
162
66.8th percentile
Trials
0
Interventional, condition-specific
Researchers
990
Distinct authors in sample
Gene link
USB1
Definitive
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
Poikiloderma with neutropenia is a rare, genetic poikiloderma disorder characterized by early-onset poikiloderma (which typically begins in the extremities, progresses centripetally and eventually involves the trunk, face and ears) associated with chronic neutropenia, recurrent infections, pachyonychia and palmoplantar keratoderma. Growth and/or develomental delay and hepato- and/or are additional reported features.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0011405
- OMIM:604173
- UMLS:C1858723
- NCIT:C177535
Additional Mondo synonyms (2)
poikiloderma with neutropenia · poikiloderma with neutropenia, Clericuzio type
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedPresent
Definitive — USB1
- LiteraturePresent
162 matched papers (103 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPartial
None under the specific name; 327 for broader category neutropenia
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (USB1).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
162
162 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
162 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
103 in the last 10 years · high confidence · 66.8th percentile (publications denominator)
Phrase hits: 162 · MeSH hits: 0
Who's working on it?
990
Distinct author names in 162 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Larizza L13 papers · 2024
Department of Medicine, Surgery and Dentistry, University of Milan, Italy. lidia.larizza@unimi.it
Papers in Europe PMC - 02Colombo EA9 papers · 2019
Dipartimento di Scienze della Salute, Università degli Studi di Milano, Via Antonio di Rudinì 8, 20142, Milan, Italy. elisaadele.colombo@unimi.it.
Papers in Europe PMC - 03Cunningham-Rundles C6 papers · 2025
Department of Medicine and Pediatrics, Mount Sinai School of Medicine, New York, NY, USA.
Papers in Europe PMC - 04Klein C6 papers · 2025
Dr von Hauner Children's Hospital, Ludwig-Maximilians-University Munich, Munich, Germany.
Papers in Europe PMC - 05Picard C6 papers · 2026
Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM UMR1163, Necker Hospital for Sick Children, Paris, France.
Papers in Europe PMC - 06Volpi L6 papers · 2016
Dipartimento di Biotecnologie Mediche e di Medicina Traslazionale, Università degli Studi di Milano, Via Viotti 3/5, 20133, Milan, Italy.
Papers in Europe PMC - 07Al-Herz W5 papers · 2020
Department of Pediatrics, Faculty of Medicine, Kuwait University, Kuwait City, Kuwait.
Papers in Europe PMC - 08Bousfiha A5 papers · 2020
Clinical Immunology Unit, Casablanca Children's Hospital, Ibn Rochd Medical School, King Hassan II University, Casablanca, Morocco.
Papers in Europe PMC - 09Casanova JL5 papers · 2020
Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM UMR1163, Necker Hospital for Sick Children, Paris, France.
Papers in Europe PMC - 10
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 327 trials are registered for neutropenia, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
high confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
327 interventional trials matched neutropenia, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: neutropenia
327
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT06293677·RECRUITING·Adjustment of Antibiotic Dosage in Pediatric Oncology Patients With Febrile Neutropenia and Augmented Renal Clearance
Conditions: Febrile Neutropenia·Matched via name phrase
- NCT05537896·RECRUITING·Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia
Conditions: Hematological Malignancy · Neutropenia·Matched via name phrase
- NCT06135896·RECRUITING·Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers
Conditions: Unresectable Pancreatic Cancer · Unresectable Bile Duct Carcinoma · Unresectable Biliary Tract Carcinoma·Matched via name phrase
- NCT06988826·NOT YET RECRUITING·Comparison of G-CSF & Antibiotics Versus Antibiotics Alone in Resolution of Febrile Neutropenia
Conditions: Febrile Neutropenia · Febrile Neutropenia, Rule of Clinical Decision, Chemotherapy · Febrile Neutropenia, Drug-Induced · G-CSF·Matched via name phrase
- NCT06926751·RECRUITING·Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid Tumors
Conditions: Solid Tumors · Children · Adolescent · Chemotherapy Induced Neutropenia·Matched via name phrase
- NCT05626530·RECRUITING·Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients
Conditions: Cytomegalovirus Infections · Infection in Solid Organ Transplant Recipients · Neutropenia · Antiviral Toxicity·Matched via name phrase
- NCT07187908·RECRUITING·Efbemalenograstim Alfa for Primary/Secondary Prevention in Patients With Solid Tumors at High Risk for Febrile Neutropenia (FN) or Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in FN
Conditions: Primary/Secondary Prevention · High Risk for Febrile Neutropenia of Chemotherapy Regimens · Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in Febrile Neutropenia·Matched via name phrase
- NCT07047352·NOT YET RECRUITING·Prospective Study Evaluate the Timing of Empirical Treatment for Carbapenem-resistant Bacterials (CROEAT Study)
Conditions: Carbapenem-resistant Enterobacterales · Neutropenia · Hematological Malignancies·Matched via name phrase
- NCT07071844·NOT YET RECRUITING·BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients
Conditions: Metastatic Colorectal Cancer·Matched via name phrase
- NCT07300735·RECRUITING·Comparing Diosmin-Hesperidin and Loratadine to Prevent Bone Pain From G-CSF in Patients With Blood Cancers
Conditions: Hematologic Malignancy · Neutropenia · Bone Pain·Matched via name phrase
- NCT07066085·RECRUITING·Serial Blood Count Study
Conditions: Cyclic Neutropenia · Congenital Neutropenia · Neutropenia·Matched via name phrase
- NCT06649448·NOT YET RECRUITING·A Multi-cohort Study of Efbemalenograstim Alfa Injection for Preventing ANC Reduction in Solid Tumor Patients Post Immune-chemotherapy.
Conditions: Solid Tumor Cancer · Chemotherapy Induced Neutropenia · G-CSF·Matched via name phrase
- NCT07578064·RECRUITING·A Randomized, Self-controlled Post-marketing Clinical Study on the Comparison of Shengbai Oral Liquid and Leucogen Tablets in the Treatment of Moderate Neutropenia Caused by Anti-tumor Drugs in Breast Cancer Patients
Conditions: Breast Cancer · Bone Marrow Suppression·Matched via name phrase
- NCT07018271·NOT YET RECRUITING·A Study on the Use of Sulpegfilgrastim to Prevent the Incidence of Neutropenia With Infection in Newly Diagnosed Non-transplant Multiple Myeloma Patients
Conditions: Multiple Myeloma · DRD · Sulpegfilgrastim · Neutropenia·Matched via name phrase
- NCT06616571·RECRUITING·Compare the Efficacy and Safety of QL0605 Injections at Different Timepoints
Conditions: Chemotherapy-Induced Febrile Neutropenia·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Poikiloderma with neutropenia" OR "Poikiloderma with neutropenia, Clericuzio type"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Poikiloderma with neutropenia" OR "Poikiloderma with neutropenia, Clericuzio type" OR "USB1" OR "constitutional neutropenia" OR "hereditary poikiloderma"
Recall-expansion terms: USB1, constitutional neutropenia, hereditary poikiloderma
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"neutropenia"
Query health: suspect — strategies attempted: phrase, recall-expansion; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T09:55:15.786Z
